What is the pathophysiology of Candida krusei infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pathophysiology of Candida krusei Infection

Candida krusei is an opportunistic fungal pathogen with distinct virulence characteristics that make it less invasive than C. albicans but particularly dangerous in immunocompromised hosts, especially those with hematologic malignancies or receiving azole prophylaxis. 1, 2

Key Pathophysiological Features

Virulence and Invasiveness

C. krusei demonstrates significantly lower intrinsic virulence compared to C. albicans in experimental models. Studies show that normal mice can resist infection with doses up to 10^8 CFU of C. krusei without mortality, whereas 10^6 CFU of C. albicans causes 100% mortality 3. This reduced pathogenicity relates to:

  • Weaker adherence to both epithelial and prosthetic surfaces
  • Lower proteolytic enzyme production
  • Reduced phospholipase activity
  • Different structural and metabolic features compared to other Candida species 4

However, this resistance is dramatically reversed by immunosuppression. When mice receive cyclophosphamide plus corticosteroids, C. krusei causes significantly shorter survival times and higher organ fungal burdens, with documented tissue invasion in all examined organs 3. This explains why C. krusei infections predominantly occur in severely immunocompromised patients.

Host Susceptibility Factors

C. krusei is the least frequently isolated of the five major Candida species but is strongly associated with specific high-risk conditions 1:

  • Hematologic malignancies and stem cell transplant recipients (most important)
  • Prolonged azole prophylaxis (creates selective pressure)
  • Severe neutropenia
  • Corticosteroid therapy
  • Geographic clustering (Northern Europe, particularly Finland)

The organism inhabits mucosal membranes of healthy individuals as a commensal but transitions to pathogenicity when host defenses are compromised 2, 4.

Mechanism of Infection Progression

The pathophysiology follows this sequence:

  1. Colonization phase: C. krusei colonizes gastrointestinal and urinary tracts, particularly when fluconazole suppresses competing C. albicans 5

  2. Translocation: In neutropenic patients, the organism translocates from mucosal surfaces (primarily gastrointestinal tract, not catheters) into bloodstream 6

  3. Dissemination: Once in bloodstream, can cause candidemia with or without deep tissue invasion. Septic shock occurs in approximately 19% of cases 1

  4. Metastatic seeding: Can establish infection in multiple organs including kidneys, liver, spleen, lungs, and heart 3, 7

Unique Biological Characteristics

C. krusei exhibits structural and metabolic features significantly different from other medically important Candida species, suggesting it may warrant taxonomic reassignment 4. Recent taxonomy has reclassified it as Pichia kudriavzevii 8.

The organism demonstrates:

  • Intrinsic resistance to fluconazole (primary mechanism: altered drug target and reduced intracellular drug accumulation) 5, 2
  • Rapid development of acquired resistance to other antifungals 2
  • Biofilm formation capacity on medical devices 7
  • Different behavior patterns toward host defenses compared to C. albicans 4

Clinical Manifestations

The pathophysiology translates into specific clinical syndromes:

  • Candidemia (most common presentation)
  • Chronic disseminated candidiasis in neutropenic patients
  • Intra-abdominal infections (particularly post-esophageal perforation)
  • Empyema (rare but serious, with 14.3% mortality) 7
  • Endocarditis, endophthalmitis, arthritis (uncommon) 4

Immune Response Dynamics

Recent research reveals that C. krusei infection triggers:

  • IL-17 and IL-23 upregulation, indicating Th17-mediated immune responses 9
  • CXCL-1 gene expression for neutrophil recruitment 9
  • Surfactant protein D activation in pulmonary infections 9

In neutropenic patients, ophthalmological findings remain minimal until neutrophil recovery, requiring delayed funduscopic examination within the first week after neutropenia resolves 6.

Critical Clinical Pitfall

The widespread use of fluconazole prophylaxis in high-risk patients creates selective pressure that eliminates susceptible Candida species while allowing C. krusei to proliferate 1, 5, 10. This represents the primary driver of increasing C. krusei infections in modern healthcare settings. The organism's intrinsic fluconazole resistance means it survives and colonizes patients receiving azole prophylaxis, then causes breakthrough invasive disease when immunosuppression deepens 5, 2.

References

Guideline

candidemia and invasive candidiasis in adults: a narrative review.

European journal of internal medicine, 2016

Research

[Candida krusei (Castellani) Berkhout--a potential pathogen with growing importance].

Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.